Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

, RHHBY

Roche

$0.00

(0.00%)

10:20
10/15/18
10/15
10:20
10/15/18
10:20

Roche breast cancer data could pressure Puma shares, says RBC Capital

RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

RHHBY

Roche

$0.00

(0.00%)

  • 16

    Oct

  • 19

    Oct

  • 07

    Nov

  • 24

    Dec

PBYI Puma Biotechnology
$42.19

-0.5 (-1.17%)

10/01/18
CANT
10/01/18
INITIATION
Target $75
CANT
Overweight
Puma Biotechnology initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Puma Biotechnology with an Overweight rating and $75 price target.
09/18/18
09/18/18
NO CHANGE
Target $151

Buy
Physician survey supports Puma's Nerlynx hitting $1B in sales, says Citi
Citi analyst Yigal Nochomovitz says his 100-physician survey of U.S. oncologists supports his "long-standing bull thesis" that Puma Biotechnology's Nerlynx is positioned to be a billion-dollar drug. Continued fundamental upside to the launch should limit investor concerns around a "stalled" launch that has been pressuring the stock, Nochomovitz tells investors in a research note. The survey indicates that one-in-four adjuvant Herceptin patients are expected to receive Nerlynx. This provides "substantive validation" that 20%-25% of Herceptin completers are high-risk and thus likely Nerlynx patients, Nochomovitz contends. The analyst lowered his price target for Puma shares to $151 from $164 and keeps a Buy rating on the name.
09/17/18
GUGG
09/17/18
INITIATION
Target $85
GUGG
Buy
Puma Biotechnology initiated with a Buy at Guggenheim
Target $85.
09/17/18
GSCO
09/17/18
INITIATION
Target $42
GSCO
Sell
Puma Biotechnology initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Paul Choi started Puma Biotechnology with a Sell rating and $42 price target. The analyst sees see 11% downside in the shares versus 20% upside on average for his coverage universe. While the company's Nerlynx launch in the extended adjuvant setting in HER2+ breast cancer has gone well to date, channel checks and analysis suggest that consensus estimates are overly optimistic with respect to patient adds in this setting, Choi tells investors in a research note. The analyst initiated coverage of the smid-cap biotech sector with a Neutral coverage view. He views sector fundamentals as healthy but says high valuations temper his enthusiasm.
RHHBY Roche
$0.00

(0.00%)

10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.
10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/03/18
PIPR
10/03/18
NO CHANGE
PIPR
Overweight
PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray
The risdiplam spinal muscular atrophy data released this morning by PTC Therapeutic (PTCT) and Roche (RHHBY) stack up fairly well to Biogen's (BIIB) Spinraza clinical data, Piper Jaffray analyst Christopher Raymond tells investors in a research note. Even taking into account all of the usual caveats regarding cross-trial comparisons, risdiplam is shaping up well compared to Spinraza, the analyst contends. He sees the new data as adding uncertainty to the Spinraza trajectory. Nonetheless, Raymond keeps an Overweight rating on shares of Biogen. The analyst made no changes to his Biogen model, but he admits risdiplam, if the data holds up, may impact Spinraza's ultimate market potential. Biogen in midday trading is up 2% to $351.41.
09/21/18
PIPR
09/21/18
NO CHANGE
Target $400
PIPR
Overweight
Biogen upcoming BIIB098 data an overlooked catalyst, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes investor sentiment on Biogen (BIIB) overlooks the H2H tolerability data for BIIB098 versus Tecfidera coming in the first half of 2018 Though BIIB098 is largely discounted as an intellectual property play "or worse," the readout, if positive, may be an important catalyst ahead of FDA approval in Q4 of 2019, Raymond tells investors in a research note. He suspects that if BIIB098 shows meaningful tolerability improvement over Tecfidera, "docs will likely take notice." Further, Raymond's new neurologist survey indicates that while the launch trends of Roche's (RHHBY) multiple sclerosis drugOcrevus "appear to be improving," other share trends, including those for Tecfidera and Tysabri, "remain stable." The analyst keeps an Overweight rating on Biogen with a $400 price target.

TODAY'S FREE FLY STORIES

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:08
10/22/19
10/22
21:08
10/22/19
21:08
Earnings
Breaking Earnings news story on Euronet »

Euronet sees Q4 EPS $1.61…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:07
10/22/19
10/22
21:07
10/22/19
21:07
Hot Stocks
Euronet says revenue growth would have been stronger if not for strong USD »

CEO Michael Brown says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:06
10/22/19
10/22
21:06
10/22/19
21:06
Hot Stocks
Euronet reports Q3 adjusted EBITDA $227.3M vs. $181.4M last year »

Reports Q3 transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:04
10/22/19
10/22
21:04
10/22/19
21:04
Earnings
Euronet reports Q3 adjusted EPS $2.84, consensus $2.80 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

FFWM

First Foundation

$15.50

0.16 (1.04%)

21:03
10/22/19
10/22
21:03
10/22/19
21:03
Earnings
First Foundation reports Q3 EPS 39c, consensus 36c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

KMB

Kimberly-Clark

$129.57

-9.74 (-6.99%)

20:36
10/22/19
10/22
20:36
10/22/19
20:36
Upgrade
Kimberly-Clark rating change at Deutsche Bank »

Kimberly-Clark upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BA

Boeing

$337.45

6.33 (1.91%)

, TMO

Thermo Fisher

$280.89

-2.56 (-0.90%)

20:25
10/22/19
10/22
20:25
10/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BA

Boeing

$337.45

6.33 (1.91%)

TMO

Thermo Fisher

$280.89

-2.56 (-0.90%)

LLY

Eli Lilly

$110.00

2.06 (1.91%)

CAT

Caterpillar

$133.69

1.47 (1.11%)

ANTM

Anthem

$260.28

7.12 (2.81%)

BX

Blackstone

$49.08

-0.025 (-0.05%)

BSX

Boston Scientific

$38.21

-0.45 (-1.16%)

GD

General Dynamics

$179.92

4.49 (2.56%)

NSC

Norfolk Southern

$188.85

2.68 (1.44%)

HLT

Hilton

$90.81

-1.57 (-1.70%)

FCX

Freeport McMoRan

$9.92

0.1 (1.02%)

IVZ

Invesco

$16.03

-0.115 (-0.71%)

OC

Owens Corning

$63.41

-0.055 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 02

    Dec

  • 07

    Dec

ACRS

Aclaris Therapeutics

$1.62

0.215 (15.36%)

20:13
10/22/19
10/22
20:13
10/22/19
20:13
Upgrade
Aclaris Therapeutics rating change at SVB Leerink »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

AMGN

Amgen

$204.84

1.93 (0.95%)

19:39
10/22/19
10/22
19:39
10/22/19
19:39
Hot Stocks
Amgen CFO David Meline to retire »

Amgen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 07

    Dec

TRV

Travelers

$130.22

-11.55 (-8.15%)

19:31
10/22/19
10/22
19:31
10/22/19
19:31
Upgrade
Travelers rating change at Deutsche Bank »

Travelers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

GOOG

Alphabet

$1,242.78

-3.45 (-0.28%)

, GOOGL

Alphabet Class A

$1,241.08

-3.15 (-0.25%)

19:09
10/22/19
10/22
19:09
10/22/19
19:09
Periodicals
State AGs plan Google antitrust meeting next month, Reuters says »

U.S. state attorneys…

GOOG

Alphabet

$1,242.78

-3.45 (-0.28%)

GOOGL

Alphabet Class A

$1,241.08

-3.15 (-0.25%)

FB

Facebook

$182.27

-7.55 (-3.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

CISN

Cision

$10.08

1.63 (19.29%)

19:03
10/22/19
10/22
19:03
10/22/19
19:03
Downgrade
Cision rating change at BMO Capital »

Cision downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MANH

Manhattan Associates

$74.47

-2.02 (-2.64%)

, TER

Teradyne

$59.24

-0.83 (-1.38%)

18:55
10/22/19
10/22
18:55
10/22/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MANH

Manhattan Associates

$74.47

-2.02 (-2.64%)

TER

Teradyne

$59.24

-0.83 (-1.38%)

CSL

Carlisle

$144.97

-0.27 (-0.19%)

USNA

Usana

$72.62

2.92 (4.19%)

NAVI

Navient

$12.16

0.19 (1.59%)

DFS

Discover

$81.30

0.85 (1.06%)

HNGR

Hanger

$20.50

0.39 (1.94%)

MRNA

Moderna

$15.90

0.42 (2.71%)

REZI

Resideo

$15.17

0.03 (0.20%)

IRBT

iRobot

$53.88

-1.82 (-3.27%)

TXN

Texas Instruments

$128.61

-2.32 (-1.77%)

INTC

Intel

$52.00

-0.12 (-0.23%)

ADI

Analog Devices

$110.91

-0.18 (-0.16%)

AVGO

Broadcom

$287.54

-2.03 (-0.70%)

NVDA

Nvidia

$195.52

-0.64 (-0.33%)

QCOM

Qualcomm

$78.46

-0.5 (-0.63%)

AMD

AMD

$31.51

-0.54 (-1.68%)

HA

Hawaiian Holdings

$30.14

0.67 (2.27%)

SIX

Six Flags

$51.22

-0.62 (-1.20%)

WHR

Whirlpool

$160.72

0.18 (0.11%)

BYD

Boyd Gaming

$26.17

0.24 (0.93%)

CMG

Chipotle

$831.69

-20.195 (-2.37%)

SNAP

Snap

$14.00

-0.58 (-3.98%)

SKX

Skechers

$38.03

0.55 (1.47%)

SLNO

Soleno Therapeutics

$1.50

0.03 (2.04%)

NOW

ServiceNow

$228.26

-12.315 (-5.12%)

NKE

Nike

$95.61

-0.61 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 31

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

  • 23

    Oct

IIPR

Innovative Industrial Properties

$72.50

-1.2 (-1.63%)

18:53
10/22/19
10/22
18:53
10/22/19
18:53
Hot Stocks
Innovative Industrial Properties investing $46.6M in two IL properties »

Innovative Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CISN

Cision

$10.08

1.63 (19.29%)

18:51
10/22/19
10/22
18:51
10/22/19
18:51
Downgrade
Cision rating change at BMO Capital »

Cision downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LOGI

Logitech

$39.97

-0.75 (-1.84%)

18:42
10/22/19
10/22
18:42
10/22/19
18:42
Hot Stocks
Logitech CEO: We had a solid quarter despite macroeconomic noise »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 05

    Nov

HAS

Hasbro

$100.00

-20.11 (-16.74%)

18:23
10/22/19
10/22
18:23
10/22/19
18:23
Hot Stocks
Hasbro CEO: We believe we can grow in Q4 »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

SPY

SPDR S&P 500 ETF Trust

$299.01

-1.04 (-0.35%)

, SPX

S&P 500

$0.00

(0.00%)

18:22
10/22/19
10/22
18:22
10/22/19
18:22
General news
Trump tweets 'good news happening' on Turkey, Syria, Middle East »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$299.01

-1.04 (-0.35%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$69.11

0.37 (0.54%)

18:20
10/22/19
10/22
18:20
10/22/19
18:20
Periodicals
NY AG's office says Exxon should pay up to $1.6B in climate trial, NYP says »

Kevin Wallace, a lawyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

XOM

Exxon Mobil

$69.11

0.37 (0.54%)

17:58
10/22/19
10/22
17:58
10/22/19
17:58
Periodicals
Exxon lawyer slams NY climate suit as trial opens, Bloomberg says »

Exxon Mobil attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

TER

Teradyne

$59.24

-0.83 (-1.38%)

17:57
10/22/19
10/22
17:57
10/22/19
17:57
Hot Stocks
Teradyne jumps 6% after quarterly results, guidance based on 5G demand »

Shares of semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

TER

Teradyne

$59.24

-0.83 (-1.38%)

17:53
10/22/19
10/22
17:53
10/22/19
17:53
Earnings
Teradyne sees Q4 EPS 73c-84c, consensus 61c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

LEVI

Levi Strauss

$17.59

0.58 (3.41%)

17:52
10/22/19
10/22
17:52
10/22/19
17:52
Hot Stocks
Levi Strauss EVP Love sells 204K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$46.15

0.48 (1.05%)

, WFC

Wells Fargo

$50.63

0.18 (0.36%)

17:51
10/22/19
10/22
17:51
10/22/19
17:51
Periodicals
BNY Mellon vice chairman leaves lender, WSJ says »

Bill Daley, former White…

BK

BNY Mellon

$46.15

0.48 (1.05%)

WFC

Wells Fargo

$50.63

0.18 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 29

    Oct

  • 12

    Nov

  • 14

    Jan

FMBI

First Midwest

$20.13

0.11 (0.55%)

17:42
10/22/19
10/22
17:42
10/22/19
17:42
Earnings
First Midwest reports Q3 adjusted EPS 52c, consensus 49c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.